Please provide your email address to receive an email when new articles are posted on . Both the 18 mg and 9 mg nerandomilast groups had smaller degrees of FVC decline vs. placebo in the U.S. subgroup ...
Nerandomilast slowed FVC decline in US IPF patients compared to placebo, with a favorable safety profile and tolerability. The FIBRONEER-IPF trial was a double-blind, placebo-controlled study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback